Recursion's REC-994 met safety and tolerability endpoints in the Phase 2 trial for CCM, but efficacy data were limited. Secondary endpoints showed trends toward reduced lesion size in the highest dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback